Live Breaking News & Updates on Myrisk hereditary cancer test
Stay updated with breaking news from Myrisk hereditary cancer test. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Myriad Genetics (NASDAQ:MYGN) Earns Equal Weight Rating from Analysts at Wells Fargo & Company themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Myriad Genetics (NASDAQ:MYGN – Get Free Report) issued an update on its FY 2023 earnings guidance on Thursday morning. The company provided EPS guidance of -0.330–0.280 for the period, compared to the consensus EPS estimate of -0.300. The company issued revenue guidance of $747.0 million-$753.0 million, compared to the consensus revenue estimate of $750.9 million. […]
Myriad Genetics (NASDAQ:MYGN) Shares Gap Up to $19.05 themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Artisan Partners Limited Partnership increased its position in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) by 15.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,538,065 shares of the company’s stock after purchasing an additional 331,207 shares during the […]
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Myriad Genetics (NASDAQ:MYGN) Shares Gap Down After Insider Selling themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Myriad Genetics (NASDAQ:MYGN – Get Free Report) updated its FY23 earnings guidance on Monday. The company provided EPS guidance of ($0.33)-($0.28) for the period, compared to the consensus EPS estimate of ($0.32). The company issued revenue guidance of $747-$753 million, compared to the consensus revenue estimate of $739.22 million. Myriad Genetics Stock Down 4.0 % […]
Myriad Genetics (NASDAQ:MYGN – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.05, Briefing.com reports. The company had revenue of $191.90 million for the quarter, compared to analysts’ expectations of $179.23 million. Myriad Genetics had a […]
Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective decreased by equities researchers at JPMorgan Chase & Co. from $17.00 to $14.00 in a report issued on Tuesday, Benzinga reports. The brokerage presently has an “underweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential downside of 21.30% […]
Myriad Genetics (NASDAQ:MYGN – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday. Several other analysts also recently issued reports on MYGN. JPMorgan Chase & Co. decreased their target price on Myriad Genetics from $18.00 to $17.00 and […]